MX2021002305A - Tratamiento de trastornos del higado. - Google Patents

Tratamiento de trastornos del higado.

Info

Publication number
MX2021002305A
MX2021002305A MX2021002305A MX2021002305A MX2021002305A MX 2021002305 A MX2021002305 A MX 2021002305A MX 2021002305 A MX2021002305 A MX 2021002305A MX 2021002305 A MX2021002305 A MX 2021002305A MX 2021002305 A MX2021002305 A MX 2021002305A
Authority
MX
Mexico
Prior art keywords
treating liver
liver disorders
disorders
manifestations
symptoms
Prior art date
Application number
MX2021002305A
Other languages
English (en)
Inventor
Randall Halcomb
Weidong Zhong
Martijn Fenaux
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of MX2021002305A publication Critical patent/MX2021002305A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En este documento se proporcionan métodos y composiciones para tratar trastornos del hígado, incluyendo sin limitación esteatohepatitis no alcohólica, y síntomas y manifestaciones de los mismos, en un paciente. En consecuencia, en este documento se utilizan compuestos de fórmulas (I), (II), etc., como se divulga en este documento.
MX2021002305A 2018-08-30 2018-08-30 Tratamiento de trastornos del higado. MX2021002305A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/103349 WO2020042114A1 (en) 2018-08-30 2018-08-30 Treating liver disorders

Publications (1)

Publication Number Publication Date
MX2021002305A true MX2021002305A (es) 2021-05-31

Family

ID=69643368

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002305A MX2021002305A (es) 2018-08-30 2018-08-30 Tratamiento de trastornos del higado.

Country Status (11)

Country Link
US (1) US20210244744A1 (es)
EP (1) EP3844156A4 (es)
JP (1) JP2022508402A (es)
KR (1) KR20210052507A (es)
CN (1) CN112771026A (es)
AU (1) AU2018438845A1 (es)
CA (1) CA3110256A1 (es)
IL (1) IL281052A (es)
MX (1) MX2021002305A (es)
SG (1) SG11202101863YA (es)
WO (1) WO2020042114A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667142A (zh) * 2019-11-08 2022-06-24 拓臻制药公司 治疗肝脏病症
CN115811972A (zh) * 2020-05-13 2023-03-17 拓臻制药公司 肝脏病症的组合治疗
EP4149453A4 (en) * 2020-05-13 2024-05-22 Terns Pharmaceuticals, Inc. COMBINATION TREATMENT OF LIVER DISEASES
IL300853A (en) 2020-08-25 2023-04-01 Lilly Co Eli SSAO inhibitor polymorphs
IL302099A (en) * 2020-10-15 2023-06-01 Lilly Co Eli FXR agonist polymorphs
MX2023005884A (es) * 2020-11-23 2023-06-26 Aclaris Therapeutics Inc Metodos para sintetizar compuestos de piridinona-piridinilo sustituidos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696910A4 (en) * 2003-09-26 2009-12-09 Smithkline Beecham Corp COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
JP2012505849A (ja) * 2008-10-15 2012-03-08 エフ．ホフマン−ラ ロシュ アーゲー 新規なベンズイミダゾール誘導体
JP2018519246A (ja) * 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途
WO2017078928A1 (en) * 2015-11-06 2017-05-11 Salk Institute For Biological Studies Fxr agonists and methods for making and using
SG11201808607SA (en) * 2016-03-28 2018-11-29 Intercept Pharmaceuticals Inc Medicine obtained by combining fxr agonist and arb
WO2017167934A1 (en) * 2016-03-30 2017-10-05 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
US20220387414A1 (en) * 2019-11-08 2022-12-08 Terns Pharmaceuticals Inc. Treating liver disorders
EP4149453A4 (en) * 2020-05-13 2024-05-22 Terns Pharmaceuticals, Inc. COMBINATION TREATMENT OF LIVER DISEASES
TW202333726A (zh) * 2021-11-11 2023-09-01 美商拓臻製藥公司 以ｓｓａｏ抑制劑治療肝病

Also Published As

Publication number Publication date
IL281052A (en) 2021-04-29
KR20210052507A (ko) 2021-05-10
EP3844156A1 (en) 2021-07-07
EP3844156A4 (en) 2022-06-08
JP2022508402A (ja) 2022-01-19
US20210244744A1 (en) 2021-08-12
CN112771026A (zh) 2021-05-07
SG11202101863YA (en) 2021-03-30
WO2020042114A1 (en) 2020-03-05
AU2018438845A1 (en) 2021-04-01
CA3110256A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2021002305A (es) Tratamiento de trastornos del higado.
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
SA518391624B1 (ar) Ror- منظمات جاما
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
WO2019178487A3 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2022005407A (es) Tratamiento de trastornos hepaticos.
EA202092278A1 (ru) Римегепант для связанных с cgrp расстройств